

Beverly Moy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8842980/publications.pdf>

Version: 2024-02-01

166
papers

6,123
citations

109264

35
h-index

76872

74
g-index

168
all docs

168
docs citations

168
times ranked

7323
citing authors

#	ARTICLE	IF	CITATIONS
1	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	5.1	451
2	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 367-377.	5.1	444
3	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2838-2848.	3.2	403
4	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With 2 HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3138-3149.	0.8	355
5	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet</i> , The, 2020, 395, 817-827.	6.3	260
6	Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1477.	3.4	259
7	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	0.8	251
8	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	0.8	229
9	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	0.8	210
10	Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2142-2150.	0.8	207
11	Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. <i>Journal of Clinical Oncology</i> , 2015, 33, 3621-3627.	0.8	172
12	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952.	0.8	148
13	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	1.1	140
14	Lapatinib: Current Status and Future Directions in Breast Cancer. <i>Oncologist</i> , 2006, 11, 1047-1057.	1.9	138
15	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology Cancer Care Ontario Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3978-3986.	0.8	127
16	American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities. <i>Journal of Clinical Oncology</i> , 2011, 29, 3816-3824.	0.8	122
17	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. <i>Oncologist</i> , 2017, 22, 1039-1048.	1.9	115
18	Lapatinib-Associated Toxicity and Practical Management Recommendations. <i>Oncologist</i> , 2007, 12, 756-765.	1.9	109

#	ARTICLE	IF	CITATIONS
19	Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience. <i>Journal of Clinical Oncology</i> , 2015, 33, 340-348.	0.8	94
20	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	15.2	83
21	Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 622-630.	0.4	77
22	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1002-1002.	0.8	71
23	Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. <i>Oncologist</i> , 2016, 21, 467-474.	1.9	70
24	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	3.4	68
25	AR Expression in Breast Cancer CTCs Associates with Bone Metastases. <i>Molecular Cancer Research</i> , 2018, 16, 720-727.	1.5	68
26	Barriers to repeat mammography: cultural perspectives of African-American, Asian, and Hispanic women. <i>Psycho-Oncology</i> , 2006, 15, 623-634.	1.0	65
27	Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches. <i>Clinical Cancer Research</i> , 2006, 12, 4790-4793.	3.2	59
28	Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. <i>Journal of Clinical Oncology</i> , 2018, 36, 3331-3339.	0.8	58
29	Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw163.	3.0	53
30	Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 787-800.	0.8	44
31	Recognizing the Financial Burden of Cancer Patients in Clinical Trials. <i>Oncologist</i> , 2015, 20, 572-575.	1.9	43
32	Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). <i>Journal of Clinical Oncology</i> , 2017, 35, 511-511.	0.8	43
33	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 3205-3221.	0.8	43
34	Announcing a New Journal Section: Community Outreach. <i>Oncologist</i> , 2016, 21, 1-1.	1.9	41
35	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
36	American Society of Clinical Oncology Policy Statement on Medicaid Reform. <i>Journal of Clinical Oncology</i> , 2014, 32, 4162-4167.	0.8	36

#	ARTICLE	IF	CITATIONS
37	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-8.	2.3	36
38	Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. <i>Biomedical Optics Express</i> , 2013, 4, 2911.	1.5	32
39	TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1005-1005.	0.8	32
40	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021, 26, e1327-e1338.	1.9	31
41	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. <i>Breast Cancer Research</i> , 2015, 17, 56.	2.2	30
42	Local/regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	1.1	30
43	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. <i>Oncologist</i> , 2021, 26, 827-834.	1.9	28
44	Patient Navigator Programs, Cancer Disparities, and the Patient Protection and Affordable Care Act. <i>Oncologist</i> , 2011, 16, 926-929.	1.9	27
45	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1057-1057.	0.8	27
46	TEACH: Tykerb Evaluation After Chemotherapy. <i>Clinical Breast Cancer</i> , 2007, 7, 489-492.	1.1	26
47	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 18.	2.3	25
48	Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. <i>Oncologist</i> , 2014, 19, 348-349.	1.9	23
49	Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 512-512.	0.8	22
50	Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). <i>Biomedical Optics Express</i> , 2017, 8, 555.	1.5	21
51	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	1.1	21
52	Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 569-578.	1.1	20
53	Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 136-143.	2.3	19
54	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	2.2	17

#	ARTICLE	IF	CITATIONS
55	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 103.	2.3	17
56	Geriatric Oncology for the 21st Century: A Call for Action. <i>Journal of Oncology Practice</i> , 2014, 10, 241-243.	2.5	16
57	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 535-544.	1.1	16
58	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1246-1262.	1.5	16
59	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. <i>Journal of Clinical Oncology</i> , 2015, 33, 508-508.	0.8	16
60	Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 733-740.	1.1	15
61	Disparities in phase 1 cancer clinical trial enrollment. <i>Cancer</i> , 2021, 127, 4464-4469.	2.0	15
62	Correlation Between Financial Relationships With Commercial Interests and Research Prominence at an Oncology Meeting. <i>Journal of Clinical Oncology</i> , 2013, 31, 2678-2684.	0.8	14
63	Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. <i>Oncologist</i> , 2014, 19, 346-347.	1.9	14
64	The Impact of Industry on Oncology Research and Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 130-137.	1.8	14
65	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5818-5827.	3.2	14
66	Debating the Oncologist's Role in Defining the Value of Cancer Care: Our Duty Is to Our Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 4039-4041.	0.8	13
67	Phase 1b trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1066-1066.	0.8	13
68	Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	3.2	12
69	Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 383, 262-272.	13.9	12
70	Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study. <i>Cancer</i> , 2019, 125, 4532-4540.	2.0	11
71	A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 515-524.	1.1	11
72	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 797-804.	2.3	11

#	ARTICLE	IF	CITATIONS
73	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 685-696.	1.3	10
74	Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. <i>Medical Decision Making</i> , 2019, 39, 642-650.	1.2	10
75	Expanding Access to Cancer Clinical Trials for Patients With Mental Illness. <i>Journal of Clinical Oncology</i> , 2019, 37, 1524-1528.	0.8	10
76	Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. <i>BMC Cancer</i> , 2020, 20, 347.	1.1	10
77	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3404-3413.	3.2	10
78	Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1020-1020.	0.8	10
79	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology Cancer Care Ontario Focused Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 822-824.	2.5	9
80	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. <i>Cancer</i> , 2015, 121, 1937-1948.	2.0	8
81	Survivorship Model of Care: Development and Implementation of a Nurse Practitioner Led Intervention for Patients With Breast Cancer. , 2017, 21, E99-E105.		8
82	Value of Cancer Care: Ethical Considerations for the Practicing Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e146-e149.	1.8	8
83	Core Elements of the Patient Protection and Affordable Care Act and Their Relevance to the Delivery of High-Quality Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , e4-e8.	1.8	7
84	Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care. <i>Oncologist</i> , 2022, 27, 518-524.	1.9	6
85	Medical Integrity Up in Smoke? Conflicts of Interest and the Lung Cancer Screening Controversy. <i>Oncologist</i> , 2008, 13, 474-476.	1.9	5
86	Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e22-e29.	1.8	5
87	FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1013-1013.	0.8	5
88	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1028-1028.	0.8	5
89	Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). <i>Breast Cancer Research and Treatment</i> , 2022, , .	1.1	5
90	No Conflict, No Interest. <i>JAMA Oncology</i> , 2016, 2, 1631.	3.4	4

#	ARTICLE	IF	CITATIONS
91	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. <i>European Journal of Cancer</i> , 2016, 56, 85-92.	1.3	4
92	Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. <i>Radiation Oncology</i> , 2020, 15, 198.	1.2	4
93	Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors. <i>Clinical Breast Cancer</i> , 2021, 21, e88-e95.	1.1	4
94	Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 540-540.	0.8	4
95	Financial burden in adult cancer survivors: Care affordability and accessibility.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6535-6535.	0.8	4
96	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1046-1046.	0.8	4
97	Randomized trial of a collaborative palliative and oncology care intervention to improve communication about end-of-life care in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1008-1008.	0.8	4
98	Financial Toxicity, Symptom Burden, Illness Perceptions, and Communication Confidence in Cancer Clinical Trial Participants. <i>JCO Oncology Practice</i> , 2022, 18, e1427-e1437.	1.4	4
99	Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER).. <i>Journal of Clinical Oncology</i> , 2020, 38, 531-531.	0.8	3
100	Antibody drug conjugates for patients with breast cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100795.	1.0	3
101	Assessment of patient navigation programs for breast cancer patients across the city of Boston. <i>Supportive Care in Cancer</i> , 2022, 30, 2435-2443.	1.0	3
102	The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 107815522097175.	0.5	2
103	Neratinib+capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and 2 prior HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 449-458.	1.1	2
104	Implementing a patient navigation program to improve adherence with cancer treatment for community health center patients newly diagnosed with cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 103-103.	0.8	2
105	Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).. <i>Journal of Clinical Oncology</i> , 2012, 30, 599-599.	0.8	2
106	Impact of PIK3CA tumor mutation on the association of aspirin or NSAID use and time to breast cancer recurrence.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1521-1521.	0.8	2
107	Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 576-576.	0.8	2
108	Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1006-1006.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Palliative care consultation for patients enrolled in cancer clinical trials.. Journal of Clinical Oncology, 2015, 33, 139-139.	0.8	2
110	Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene. Oncologist, 2015, 20, 571-571.	1.9	1
111	The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?. Oncologist, 2016, 21, 1411-1413.	1.9	1
112	Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and â%¥2 prior HER2-directed regimens. , 2021, , .		1
113	Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA).. Journal of Clinical Oncology, 2021, 39, 1570-1570.	0.8	1
114	Financial toxicity, symptom burden, illness perceptions, and communication confidence in cancer clinical trial participants.. Journal of Clinical Oncology, 2021, 39, 86-86.	0.8	1
115	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. Journal of Clinical Oncology, 2015, 33, 117-117.	0.8	1
116	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.. Journal of Clinical Oncology, 2017, 35, TPS1106-TPS1106.	0.8	1
117	Implementation of a brief screening tool to identify needs of cancer survivors.. Journal of Clinical Oncology, 2019, 37, e23075-e23075.	0.8	1
118	Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases.. Journal of Clinical Oncology, 2020, 38, 1094-1094.	0.8	1
119	Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer.. Journal of Clinical Oncology, 2013, 31, 147-147.	0.8	1
120	Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence.. Journal of Clinical Oncology, 2015, 33, 6553-6553.	0.8	1
121	Hospitalizations and emergency department use in cancer clinical trial patients.. Journal of Clinical Oncology, 2015, 33, 160-160.	0.8	1
122	Enhancing Health Equity Through Cancer Health Economics Research. Journal of the National Cancer Institute Monographs, 2022, 2022, 74-78.	0.9	1
123	Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1). Cancer Research, 2022, 82, P1-14-02-P1-14-02.	0.4	1
124	NIMG-63. ADVANCED IMAGING FOR ASSESSING VOLUMETRIC RESPONSES IN BRAIN METASTASES TREATED WITH CHECKPOINT BLOCKADE. Neuro-Oncology, 2018, 20, vi190-vi190.	0.6	0
125	Abstract PS18-19: Comparison of metastatic genomic profile in patients â%45 years and patients >45 years with triple-negative breast cancer. , 2021, , .		0
126	Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
127	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 3059-3059.	0.8	0
128	Illness perceptions, financial toxicity, symptom burden, and survival in cancer clinical trial (CCT) participants.. Journal of Clinical Oncology, 2021, 39, 160-160.	0.8	0
129	Association between financial relationships with commercial interests and researchÂmerit at the ASCO Annual Meeting (AM).. Journal of Clinical Oncology, 2012, 30, 6095-6095.	0.8	0
130	Financial relationships with commercial interests (COI) among abstracts at the ASCO Annual Meeting.. Journal of Clinical Oncology, 2012, 30, 6128-6128.	0.8	0
131	Lapatinib in HER2+ early breast cancer: Quality of life analysis.. Journal of Clinical Oncology, 2012, 30, 604-604.	0.8	0
132	Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.. Journal of Clinical Oncology, 2012, 30, 596-596.	0.8	0
133	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 630-630.	0.8	0
134	Risk perceptions in localized breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 9534-9534.	0.8	0
135	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 533-533.	0.8	0
136	NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction.. Journal of Clinical Oncology, 2013, 31, 6557-6557.	0.8	0
137	Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 647-647.	0.8	0
138	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 145-145.	0.8	0
139	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 167-167.	0.8	0
140	Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, 522-522.	0.8	0
141	Alleviating financial burden for cancer patients in clinical trials.. Journal of Clinical Oncology, 2014, 32, 10-10.	0.8	0
142	Financial burden of cancer clinical trials: Impact of an equity program intervention.. Journal of Clinical Oncology, 2015, 33, 6501-6501.	0.8	0
143	Prospective study of the financial burden of cancer clinical trial patients referred to a cancer care equity program (CCEP).. Journal of Clinical Oncology, 2016, 34, e18056-e18056.	0.8	0
144	Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 586-586.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Breast cancer care redesign as an approach to streamline survivorship care: Outcomes and challenges.. Journal of Clinical Oncology, 2017, 35, 9-9.	0.8	0
146	Are NCI-designated cancer centers websites linguistically accessible?. Journal of Clinical Oncology, 2017, 35, e18078-e18078.	0.8	0
147	Addressing financial concerns of cancer clinical trial participants: Longitudinal outcomes of an equity intervention.. Journal of Clinical Oncology, 2018, 36, 6566-6566.	0.8	0
148	Considering cost and value with patients in clinic.. Journal of Clinical Oncology, 2018, 36, e18905-e18905.	0.8	0
149	Delays in initial breast cancer treatment among black and white women in Boston.. Journal of Clinical Oncology, 2018, 36, e18620-e18620.	0.8	0
150	Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.. Journal of Clinical Oncology, 2018, 36, 1021-1021.	0.8	0
151	Working together in cancer care: An academic community partnership for a diverse patient population.. Journal of Clinical Oncology, 2019, 37, 10525-10525.	0.8	0
152	Medical oncologists'™ perceptions of clinical trials for underrepresented populations.. Journal of Clinical Oncology, 2020, 38, e19062-e19062.	0.8	0
153	Factors associated with frequent insomnia among breast cancer survivors.. Journal of Clinical Oncology, 2020, 38, e24098-e24098.	0.8	0
154	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.. Journal of Clinical Oncology, 2020, 38, 2529-2529.	0.8	0
155	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. Neuro-Oncology, 2020, 22, ii147-ii147.	0.6	0
156	Abstract P3-13-01: Association of polygenic risk score with 2 year risk of poor prognosis breast cancer. Cancer Research, 2022, 82, P3-13-01-P3-13-01.	0.4	0
157	Abstract P3-09-11: Clinical characteristics associated with BRCA1/2 mutations identified on routine tumor tissue genotyping in metastatic breast cancer. Cancer Research, 2022, 82, P3-09-11-P3-09-11.	0.4	0
158	Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation. Cancer Research, 2022, 82, P1-18-22-P1-18-22.	0.4	0
159	Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App. Cancer Research, 2022, 82, P4-12-08-P4-12-08.	0.4	0
160	Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors. Cancer Research, 2022, 82, P3-23-02-P3-23-02.	0.4	0
161	Abstract PD5-11: Pilot study to assess prolonged nightly fasting in breast cancer survivors (LONGFAST). Cancer Research, 2022, 82, PD5-11-PD5-11.	0.4	0
162	Abstract P3-16-01: Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC). Cancer Research, 2022, 82, P3-16-01-P3-16-01.	0.4	0

#	ARTICLE	IF	CITATIONS
163	CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, CLO22-033.	2.3	0
164	Utilizing Natural Language Processing (NLP) to identify breast cancer associated-lung metastases from pathology reports to delineate characteristics and challenges of this common site of breast cancer recurrence.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13592-e13592.	0.8	0
165	Adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12521-e12521.	0.8	0
166	Baseline preferences for digital information engagement in patients with breast cancer by age and status of diagnosis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24119-e24119.	0.8	0